Appio brings deep institutional familiarity to the position, having previously led Bausch Health—the parent company of Bausch + Lomb—since 2022. He has served as chairman of the board for Bausch + Lomb since August, a tenure that directors believe provides the necessary continuity to maintain the firm's current growth trajectory.

Alongside the executive shuffle, Bausch + Lomb signaled an optimistic financial forecast. The company expects to raise its full-year adjusted Ebitda outlook, though specific figures remain under wraps. Investors will have to wait until October 28, when the firm concludes its current blackout period and releases its third-quarter earnings report, to see the full scope of those revisions.